Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Scienture Holdings Inc

SCNX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$0.46

▼ -1.29%

Market Cap $18.85M · Vol 1.40M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$18.85M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+25.77%

YoY

RSI (14)

74.17

Momentum

Beta

3.35

vs Market

52W High

$2.60

82.35% below

52W Low

$0.24

92.61% above

Volume

1.40M

Avg 279.27K

P/B

0.30

Price-to-book

ROE

N/A

Return on equity

Free Float

86.69%

Public shares

Shariah Compliance8 STANDARDS

✗ Scienture Holdings Inc (SCNX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SCNX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+20.76%

+17.99%

+11.68%

+6.00%

YTD

-10.00%

-62.07%

-90.58%

-98.98%

Financials & Valuation

TTM · Annual

Total Revenue	$431.61K
Net Income	$-41,512,260.00
Revenue Growth (YoY)	N/A
Gross Margin	76.80%
Operating Margin	-3,763.78%
Net Profit Margin	-9,618.03%
ROE	N/A
ROA · ROIC	-46.03% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	18.13
P/B	0.30
P/FCF	N/A
EPS Growth	+25.77%
Outstanding Shares	41.06M

Technical Indicators

50-Day SMA	$0.38
200-Day SMA	$0.46
RSI (14)	74.17
Beta	3.35
52-Week High	$2.60
52-Week Low	$0.24

Volume Today	1.40M
Avg Daily Volume (30D)	279.27K
Relative Volume	5.00x
Volatility (10D)	68.88
Volatility (30D)	68.76
Free Float	86.69%

Analyst Consensus

BUY

Current Price $0.46

Mean Target $1.50

52W Low$0.24 52W High$2.60

Current

Target

$0.24 $2.60

Current Analyst target

+226.80% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001STZBS0

ISINUS80880X1046

CountryUnited States of America

Sub-IndustryPharmaceuticals Wholesale

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

MCK McKesson Corp +1.44% CAH Cardinal Health, Inc +1.70% SIG.AX Sigma Healthcare Ltd +0.00% 000963.SZ Huadong Medicine Co Ltd +0.54% HLUN A.CO H Lundbeck A/S +0.56%

Company Profile

Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.